What Happened
Federal regulators are moving against online sellers of unapproved weight-loss injections on two fronts at once: the product itself, and the way buyers are told to measure it.
In a September 24, 2026 warning letter made public this week, the Food and Drug Administration told the operator of Cheap Medicine Shop to stop offering unapproved and misbranded injectable semaglutide to U.S. consumers. The letter warns that drugs sold outside regulatory safeguards may contain contaminants, incorrect ingredients or inconsistent amounts of active medication.
Separately, the agency issued a safety alert describing a failure mode that has nothing to do with the drug's chemical identity. Patients using compounded semaglutide from multidose vials measured several times their intended dose, according to FDA, and reported vomiting, abdominal pain, fainting and dehydration. Some required hospital care. The agency identified confusion between milligrams, milliliters and syringe "units," combined with differing concentrations between products, as the root of the errors.
The scale of reported harm is documented but incomplete. As of May 31, 2026, FDA had logged 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. The agency notes those reports do not establish that the medication caused every event, do not indicate what share of users was affected, and are likely underreported.
Who Is Affected
Buyers who purchase injectable GLP-1s from websites without a prescription or medical screening; the clinicians who inherit them mid-treatment; and legitimate compounding pharmacies, which now operate under rules a gray-market seller ignores. FDA maintains that compounding can be appropriate when an approved medicine cannot meet a specific patient's needs — the objection is to unapproved products marketed as equivalents.
Timeline
- Ongoing — FDA monitors internet sales of semaglutide and tirzepatide and issues warning letters to distributors.
- May 31, 2026 — adverse-event counts reach 990 for compounded semaglutide, 730-plus for compounded tirzepatide.
- September 24, 2026 — warning letter issued to Cheap Medicine Shop over unapproved, misbranded injectable semaglutide.
- November 9, 2026 — the letter and the measuring-error alert reach national coverage.
What This Means for Researchers
Two distinct risks are conflated in most coverage, and they deserve separating. One is a purity problem: an unverified vial may contain the wrong molecule, a degraded one, or an unknown concentration. The other is a measurement problem: even a correctly labeled vial can be drawn wrong when the label speaks in milligrams, the syringe speaks in units, and no clinician checks the arithmetic.
The second risk is the more instructive one, because it survives better testing. A perfect certificate of analysis does not catch a vial whose concentration differs from the last one the buyer used. Verification and instruction are separate controls.
How to Verify Your Peptides
Start with how testing works for the analytical chain, then identity, purity and fill-weight for what a genuine certificate of analysis should report. Fill weight matters specifically here: a vial that is underfilled concentrates every subsequent measurement.
FDA's warning signs are worth memorizing. Be skeptical of sellers that ship without medical screening or a prescription, have no licensed clinician for follow-up questions, claim a compounded product is identical to an approved drug, or send damaged packaging with no instructions.
Safe Alternatives
Approved, fully labeled GLP-1 therapies are documented in our peptide library, including semaglutide and tirzepatide. Our vendor directory tracks suppliers that publish third-party testing documentation.
Sources
Regulatory announcements — FDA warning letter to Cheap Medicine Shop, September 24, 2026; FDA safety alert on compounded semaglutide measuring errors; FDA adverse-event data through May 31, 2026. Industry reports.